Engagement note
What the First 90 Days Look Like
For biotech-shaped AI-oncology companies — those running their own programs toward an IND under their own name. A parallel variant exists for AI-platform companies.
The detailed phase-by-phase content for this engagement note is being prepared for the website. JGN has reviewed and marked the canonical version in the vault; the public-facing version is integrated here pending final layout polish.
Placeholder note. This page will hold the full text of the biotech-shaped 90-Days engagement note, including the four phases (Diagnostic → Endpoint and indication → Trial design and FDA interaction plan → Regulatory translation and handoff), the Calibration Map decision fields, the expansive-then-decisive arc inside Phase 2, the Strategic Theme one-pager as the Phase 4 portable summary, and the explicit COI-awareness note around the Next-Stage CMO Recommendation.
The full vault source — including the v1.4 calibration-map decision fields you marked — will be integrated into this page once the JGN markup is shared and reconciled with the website's typographic conventions.